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Abstract 
Background: Similar to tumor cells, activated T-lymphocytes generate ATP mainly by glycolytic 
degradation of glucose. Lymphocyte glucose uptake involves non-concentrative glucose carriers 
of the GLUT family. In contrast to GLUT isoforms, Na+-coupled glucose-carrier SGLT1 accumulates 
glucose against glucose gradients and is effective at low extracellular glucose concentrations. The 
present study explored expression and regulation of SGLT1 in activated murine splenic cytotoxic 
T cells (CTLs) and human Jurkat T cells. Methods: FACS analysis, immunofluorescence, confocal 
microscopy, chemiluminescence and Western blotting were employed to estimate SGLT1 
expression, function and regulation in lymphocytes, as well as dual electrode voltage clamp in 
SGLT1 ± JAK3 expressing Xenopus oocytes to quantify the effect of janus kinase3 (JAK3) on SGLT1 
function. Results: SGLT1 is expressed in murine CTLs and also in human Jurkat T cells. 2-(N-(7-
nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose uptake was significantly decreased by 
SGLT1-blocker phloridzin (0.2 mM) and by pharmacological inhibition of JAK3 with WHI-P131 
(156 µM), WHI-P154 (11.2 µM) and JAK3 inhibitor VI (0.5 µM). Electrogenic glucose transport 
(Iglucose) in Xenopus oocytes expressing human SGLT1 was increased by additional expression 
of human wild type JAK3, active A568VJAK3 but not inactive K851AJAK3. Coexpression of JAK3 
enhanced the maximal transport rate without significantly modifying affinity of the carrier. Iglucose 
in SGLT1+JAK3 expressing oocytes was significantly decreased by WHI-P154 (11.2 µM). JAK3 
increased the SGLT1 protein abundance in the cell membrane. Inhibition of carrier insertion by 
brefeldin A (5 µM) in SGLT1+JAK3 expressing oocytes resulted in a decline of Iglucose, which was 
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similar in presence and absence of JAK3. Conclusions: SGLT1 is expressed in murine cytotoxic T 
cells and human Jurkat T cells and significantly contributes to glucose uptake in those cells post 
activation. JAK3 up-regulates SGLT1 activity by increasing the carrier protein abundance in the 
cell membrane, an effect enforcing cellular glucose uptake into activated lymphocytes and thus 
contributing to the immune response. 
IntroductionThe tyrosine kinase, janus kinase 3 (JAK3) contributes to the signaling of hematopoietic cell cytokine receptors [1-5]. In lymphocytes and tumor cells JAK3 fosters cell proliferation and counteracts apoptosis [6-8]. Accordingly, JAK3 inhibitors stimulate apoptosis of tumor cells [9, 10]. In contrast, JAK3 fosters apoptosis of dendritic cells [11]. JAK3 has been implicated in the response to hypoxia and ischemia-reperfusion [12-14]. The gain of function mutation of A572VJAK3 [15] has been found in acute megakaryoplastic leukemia [16, 17]. Replacement of the ATP coordinating lysine by alanine in the catalytic subunit results in the inactive K855AJAK3 [15].Cellular functions regulated by JAK3 include glucose metabolism [12]. The isoform JAK2 has previously been shown to up-regulate the Na+ coupled glucose carrier SGLT1 [18], which mediates secondary active transport driven by the electrochemical Na+ gradient [19]. SGLT1 and its isoform SGLT2 are expressed in epithelial cells and accomplish the concentrative cellular uptake of glucose from the intestinal or renal tubular lumen across the apical cell membrane [19]. SGLT1 is further expressed in a wide variety of tumor cells [20-27]. Tumor cells meet their need for energy mainly by glycolysis [22, 28-31]. In tumor tissue, the excessive cellular glucose uptake may result in a sharp decrease of extracellular glucose concentrations requiring concentrative cellular uptake for the maintenance of adequate intracellular glucose concentrations. Unlike the facilitative glucose carriers the Na+-coupled glucose carriers could transport against a chemical gradient and allow cellular glucose accumulation even at low extracellular glucose concentrations [19]. Mechanisms upregulating SGLT1 expression and activity in tumor cells involve EGF receptor dependent stabilization of SGLT1 [21, 27] and stimulation of SGLT1 by JAK2 [18]. Moreover, SGLT1 is upregulated by the HPV18 E6 protein from human papilloma virus [32], the causative agent of cervical cancer, other anogenital cancers and a subset of head and neck carcinomas [33-35].Similar to tumor cells, activated T lymphocytes [36] and other monocytes depend on glycolysis for ATP production during infection. Following activation T cells switch from oxidative phosphorylation prevailing in naive cells to glycolysis thus providing oxygen-independent ATP production [36]. Effector CTLs may have to migrate, survive and produce 
effector cytokines in the hypoxic environment of inflammatory tissue. Moreover, lymphoid tissue is also relatively hypoxic with oxygen tension ranging from 1 to 5% [37]. A switch to glycolysis may thus allow CTLs to proliferate and mediate their effector function in relatively hypoxic conditions [38]. Effector T cells (Teff) are particularly dependent on glycolysis, while regulatory T cells (Tregs) generate ATP in large part by lipid oxidation [39]. Lymphocyte glycolysis is stimulated by activation of the Interleukin 7 receptor [40], which may activate JAK3 [31]. Besides its role in energy supply, glycolysis may provide a source of carbon for the synthesis of nucleic acids and phospholipids [41]. The dependence of CTLs on glycolysis 
renders those cells dependent on efficient glucose uptake for survival and function [42, 43].Similar to T lymphocytes, B lymphocytes [44], macrophages [45-47] and mast cells [40] may generate ATP in large part by glycolysis.
At least in theory, facilitative glucose uptake may become insufficient in tissues with low extracellular glucose concentration. The present study thus explored whether SGLT1 is expressed in activated T lymphocytes from mice and in human Jurkat T cells and whether SGLT1 contributes to glucose uptake by those cells. Moreover, the present study explored 
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whether SGLT1 is regulated by JAK3. To this end cytotoxic T cells cultured from wild type mice were activated with anti-CD3 for 48h and later cultured in IL2 supplemented medium to generate mature cytotoxic T cell blasts. SGLT1 expression was analysed by FACS analysis, confocal microscopy and Western blotting. Moreover, glucose uptake was determined in the absence and presence of SGLT1 inhibitor phloridzin and JAK3 inhibitors WHI-P131, WHI-P154 and JAK3 inhibitor VI. In an 
additional series of experiments, the influence of JAK3 on SGLT1 activity was determined in 
Xenopus laevis oocytes. SGLT1 was expressed in Xenopus oocytes with or without wild type JAK3, active A568VJAK3 or inactive K851AJAK3 and SGLT1 protein abundance in the cell membrane determined by chemiluminescence as well as electrogenic glucose transport utilizing dual electrode voltage clamp.
Materials and Methods
Culture of Jurkat T cells and Caco2 cellsHuman Jurkat T cells [48] were cultured in RPMI 1640 supplemented with 10% FBS, 1% penicillin/streptomycin, HEPES, L-glutamine, sodium-pyruvate, NEAA- non-essential amino acids and 
ß-mercaptoethanol at 37°C in a humidified atmosphere with 5% CO2 / air.  Caco2 cells were cultured in DMEM medium containing 4.5 g/L glucose, 20% FBS, 1% L-glutamine, 1% non-essential amino acids and 1% penicillin/streptomycin. The cells were grown on 12-mm glass coverslips (neoLab Migge Laborbedarf-Vertriebs GmbH, Heidelberg, Germany) in 12-well plates (5×104 cells/well/
coverslip). Two days after plating, the cells reached 80–90% confluence and were used as positive control for confocal staining of SGLT1.
Splenic CD8+ cytotoxic T-lymphocyte culture from mice All animal experiments were conducted according to German law and approved by the respective authority. Spleens were isolated from B6129SF2/J male and female wildtype mice as well as from SGLT1 knockout mice [49]. Cytotoxic T lymphocytes (CTL) were cultured from the splenic T-cells as described earlier [50]. For activation of primary naive T cells, spleens from wildtype mice were disaggregated following red blood cell lysis. Cells were cultured in RPMI-1640 medium containing 50 mM L-glutamine, 10% heat-inactivated FBS, 50 μM β-mercaptoethanol and 1% penicillin-streptomycin. Single-cell suspensions from splenocytes adjusted to a density of 5×106 cells/mL were stimulated with monoclonal anti-CD3 (5 μg/mL; 145-2C11, R and D Systems) to 'trigger' the T-cell receptor (TCR). For generation of mature cytotoxic T-lymphoblasts, mouse T cells grown from spleen preparations cultured for 48 h in the presence of stimulus (monoclonal antibody 2C11) were washed and resuspended at a density of 4×105 cells per mL with IL-2 (0.02 μg/mL; 360 IU/mL) for 72 h to generate mature CTL blasts. After activation and clonal expansion mature cytotoxic 
T-cell blasts were characterized phenotypically by flow cytometry. As a result, more than 80% of the cells were positive for CD8+. Cells were further maintained in medium containing IL-2 (0.02 μg/mL; 360 IU/mL). Cells were counted each day, and maintained to the optimum cell density with IL-2 supplementation in the medium.
Flow cytometric analysis and phenotyping of the cells
Mature cytotoxic T-cell blasts were analysed with the standard multicolor flow cytometry settings and 
commercially available specific fluorescence conjugated antibodies as follows: Fluorescein isothiocyanate (FITC) or Phycoerythrin (PE) conjugated anti-CD4, Allophycocyanin (APC) or Cyanine 5.5 (Cy5.5) conjugated anti-CD8, PE conjugated anti-CD25, PE conjugated anti-CD62L, APC conjugated anti-CD25, PE conjugated anti-CD98, PE-anti-CD71 and APC anti-TCRbeta (BD Biosciences, Heidelberg, Germany). A minimum of 2x105 cells were washed and stained for 30 min at 4°C with saturating concentrations of antibody in RPMI-1640 medium and 0.5% FBS. Cells were washed and resuspended in RPMI-1640 medium and 0.5% FBS before being acquired on a FACS Calibur (BD, Heidelberg, Germany). A minimum of 5×104 relevant events were measured and stored ungated. Live cells (>90% of total acquired events) were gated according to their forward scatter and side scatter. Data was analyzed using Cell Quest Pro software (BD Biosciences, Heidelberg, Germany).  
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SGLT1 flow cytometry
Cell surface expression of SGLT1 was determined using specific antibodies for human (Millipore, Billerica, MA, USA) and murine SGLT1 described earlier [49]. A minimum of 2x105 cells were washed with PBS and stained with primary anti-SGLT1 antibody for at least 6 h followed by washing twice with ice-
cold PBS and staining with corresponding secondary goat anti-rabbit FITC conjugated antibody (1:500, 
Invitrogen, Darmstadt, Germany) for 1 h. After washing with PBS cells were analyzed by flow cytometry. FITC 
fluorescence intensity was measured in FL-1 fluorescence channel on a FACS calibur (BD, Heidelberg, Germany). A minimum of 5×104 relevant events were collected and stored ungated. Live cells (>90% of total acquired events) were gated according to their forward scatter and side scatter. Data were analyzed using Cell Quest Pro 
software (BD Biosciences, Heidelberg, Germany). To determine expression on specific CD8+/CD4+ cell subsets in murine CTLs, cells were stained in addition with PE-conjugated anti-CD4 antibody and APC-conjugated anti-
CD8 antibody (BD Biosciences, Heidelberg, Germany). The fluorescence was measured by standard multicolor 
flow cytometry settings. PE fluorescence measured in FL-2 and APC fluorescence measured in FL-4 channel 
together with FITC fluorescence measured in channel FL-1.
SGLT1 mRNA expression
Total RNA was isolated from total CTLs, purified CD4+ T cells and purified CD8+ T cells activated for 48 hours in presence of IL-2 (0.02 μg/mL; 360 IU/mL) and anti-CD3 (5 μg/mL) by mRNAeasy isolation kit (QIAGEN, Germany) according to manufacturer’s instructions and 1 µg RNA was converted into cDNA using Superscript III reverse transcriptase cDNA synthesis kit (Invitrogen, Germany). RT-PCR reaction was set up using 10 ng cDNA using 2x KAPA-SYBR Green (Peqlab, Germany) and forward as well as reverse primers for SGLT1 expression. Real-time quantitative RT-PCR analysis was performed using BioRad CFX96 Real-Time thermal cycler (BioRad, USA). The relative expression level of miRNAs was normalized to that of internal control GAPDH by using the 2-∆∆Ct cycle threshold method as described previously [51].  
The following primers were used:SGLT-1-F 5’- TGCACCTGTACCGTTTGTGT-3’SGLT-1-R 5’- GGGGGCTTCTGTGTCTATTT-3’,GAPDH-F 5’-TCTGACCACAGTGAGGAATGTCCAC-3’GAPDH-R 5’-TTGATGGCAACAATCTCCAC-3’
Cellular glucose uptake 
The fluorescent glucose analogue 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose (2-NBD-glucose; Invitrogen, Darmstadt, Germany) was used to measure the relative uptake of glucose by 
flow cytometry. In each condition, cells (1 × 106) were incubated with 2-NBD-glucose (30 μM) in phosphate 
buffered saline for 1 hour at 37°C, subsequently washed twice in cold PBS and analyzed by flow cytometry in 
fluorescence channel FL1. Changes in glucose uptake after inhibitor treatment were calculated as differences 
in geometric mean of the fluorescence. Flow cytometry settings were made by standard protocols relative to the unstained cells.To determine the effect of phloridzin on total glucose uptake by CTLs and Jurkat T cells, cells (1 × 106)  were incubated with the indicated concentrations of phloridzin (Sigma Aldrich, Taufkirchen München, Germany) in cell culture medium for the indicated time periods. Following incubation cells were washed and glucose uptake measured as described above in the continuous presence or absence of phloridzin. In some experiments phloridzin was added only in the 2-NDB-glucose uptake solution without any pre-incubation with the inhibitor. To determine the effect of JAK3 inhibition on glucose uptake, cells (1 × 106) were treated for 12 h with 
the JAK3 inhibitors WHI-P131/JANEX-1 (4-(4′-Hydroxyphenyl)amino-6,7-dimethoxyquinazoline, 156 µM), 
WHI-P154 (4-[(3′-Bromo-4′-hydroxyphenyl)amino]-6,7-dimethoxyquinazoline, 11.2 µM) or JAK3 Inhibitor VI (0.5 µM) (Calbiochem, Merck KGaA, Darmstadt, Germany). At the end of the incubation period cells were washed with PBS and glucose uptake determined as described above. For each condition untreated cells were used as control. 
Immunostaining and confocal microscopy
SGLT1 protein abundance was determined by immunofluorescence. The cells (1x 106) were washed 
with PBS and fixed for 20 min in 4% paraformaldehyde in PBS/0.1% Triton. The cells were washed again and then blocked in 5% goat serum in PBS/0.1% Triton for 1 hour at room temperature. To detect the expression of SGLT1 the cells were incubated overnight at 4°C with specific antibodies for human (Millipore, 
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Billerica, MA, USA) and murine rabbit anti-SGLT1 described earlier [49]. After incubation, the cells were rinsed three times with PBS/0.1% Triton and incubated with the secondary FITC anti-rabbit antibody 
(1:500, Invitrogen, Darmstadt, Germany) for 1 h at room temperature. After washing with PBS/0.1% Triton 
the nuclei were stained with DRAQ-5 dye (1:1000, Biostatus, Leicestershire, UK) for 5 min at 37°C. The slides were mounted with Prolong antifade reagent (Invitrogen, Darmstadt, Germany). The images were taken on a Zeiss LSM 5 EXCITER Confocal Laser Scanning Microscope, equipped with a 405–633 nm laser 
(Carl Zeiss MicroImaging GmbH, Germany) using a water immersion Plan-Neofluar 63/1.3 NA DIC. Three independent experiments were performed for each set of experiments.
Western blottingThe cells were lysed  in cell lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Triton X-100, 0.5% 
SDS, 1 mM NaF, 1 mM Na3VO4, 0.4% ß-mercaptoethanol) containing protease inhibitor cocktail (Sigma). 100-50 µg of protein were solubilized in Laemmli sample buffer at 95°C for 5 min and resolved by 10% SDS-PAGE. For immunoblotting proteins were electro-transferred onto a nitrocellulose membrane and blocked with 5% nonfat milk in TBS-0.10% Tween 20 (TBST) at room temperature for 1 hour. Then, the 
membrane was incubated with affinity purified anti-SGLT1 antibody (1:1000, rabbit polyclonal antibody, Millipore, Billerica, MA, USA) or with murine rabbit anti-SGLT1 at 4°C overnight. After washing 3 times with TBST (10 min each) the blots were incubated with horseradish peroxidase conjugated secondary anti-
rabbit antibody (1:2000; Cell Signaling Technology, MA, USA) for 1 hour at room temperature. After washing antibody binding was detected with the ECL detection reagent (Cell Signaling Technology, MA, USA). For loading control the same membranes were stripped with stripping buffer (Millipore, Billerica, MA, USA) and 
reblotted with rabbit anti-α/β-Tubulin antibody (1:1000; Cell Signaling Technology, MA, USA). Antibody-
binding was quantified with Quantity One Software (Biorad, Germany).
ConstructsFor generation of cRNA, constructs were used encoding wild-type human SGLT1 (SLC5A1) and wild-type murine JAK3 (Imagenes, Berlin, Germany) [52, 53]. Further, an inactive K851AJAK3 mutant, corresponding to human K855AJAK3 mutant [15] and the active A568VJAK3 mutant, corresponding to human A572VJAK3 mutant [15] were generated by site-directed mutagenesis (QuikChange II XL Site-Directed Mutagenesis Kit; Stratagene, 
Heidelberg, Germany) according to the manufacturer’s instructions [54]. The following primers were used: A568VJAK3:5´ GAGTCTTTTCTGGAAGTCGCAAGCTTGATGAGC 3´; A568VJAK3: 5´ GCTCATCAAGCTTGCGACTTCCAGAAAAGACTC 3´K851AJAK3: 5´ CCCCTGGTGGCAGTGGCACAGCTACAGCACAGC 3´andK851AJAK3: 5´GCTGTGCTGTAGCTGTGCCACTGCCACCAGGGG 3´.Underlined bases indicate mutation sites. The mutants were sequenced to verify the presence of the desired mutation. The mutants were used for generation of cRNA as described previously [55-57].
Voltage clamp in Xenopus oocytes
Xenopus oocytes were prepared as previously described [58-60]. 10 ng of wild type JAK3 cRNA were 
injected on the first day and 10 ng SGLT1 cRNA on the same day after preparation of the oocytes. The oocytes were maintained at 17°C in ND96 solution containing (in mM): 96 NaCl, 4 KCl, 1.8 MgCl2, 0.1 CaCl2, 5 HEPES, pH 7.4, supplemented with theophyllin (90 mg/L), gentamycin (100 mg/L), tetracyclin (50 mg/L) and 
ciprofloxacin (1.6 mg/L). The final solutions were titrated to pH 7.4 using NaOH. Where indicated, WHI-P154 
(4-[(3′-Bromo-4′-hydroxyphenyl)amino]-6,7-dimethoxyquinazoline, 11.2 µM), actinomycin D (10 µM) or brefeldin A (5 µM) were added. The voltage clamp experiments [61-63] were performed at room temperature 3 days after injection. Two-electrode voltage-clamp recordings were performed at a holding potential of -70 mV. 
The data were filtered at 10 Hz and recorded with a Digidata A/D-D/A converter and Clampex V.9 software for data acquisition and analysis (Axon Instruments)[64-66]. The control superfusate (ND96) contained 96 mM NaCl, 2 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2 and 5 mM HEPES, pH 7.4. Glucose was added to the solutions at a 
concentration of 10 mM unless otherwise stated. The flow rate of the superfusion was approx. 20 mL/min, and a complete exchange of the bath solution was reached within about 10 s [67-69]. 
Detection of SGLT1 cell surface expression by chemiluminescence
Defolliculated oocytes were incubated with rabbit polyclonal anti-SGLT1 antibody (1:200) and 
subsequently with secondary, HRP-conjugated goat anti-rabbit antibody (1:1500, Cell Signaling Technology, 
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MA, USA). Post-staining individual oocytes were placed in 96 well plates with 20 µl of SuperSignal ELISA Femto Maximum Sensitivity Substrate (Pierce, Rockford, IL, USA) and chemiluminescence of single oocytes was 
quantified in a luminometer (Walter Wallac 2 plate reader, Perkin Elmer, Juegesheim, Germany) by integrating the signal over a period of 1 s. Results display normalized relative light units [70, 71].
Statistical analysisData are provided as means ± SEM, n represents the number of oocytes and mice investigated. All experiments were repeated with at least 3 batches of oocytes; in all repetitions qualitatively similar data were obtained. As expression of SGLT1 and/or JAK3 may vary from batch to batch of oocytes, comparisons were always made within the same oocyte batch. Data were tested for significance using ANOVA or t-test, as 
appropriate. Results with p<0.05 were considered statistically significant.
Results
Expression of SGLT1 and phloridzin sensitive glucose uptake in activated murine cytotoxic 
T lymphocytes SGLT1 expression in murine cytotoxic T lymphocytes was detected with 
immunofluorescence and confocal microscopy. As shown in Fig.1A, SGLT1 is mainly localized in the cell membrane. Control staining with secondary antibody alone did not result in any 
significant fluorescence signal (not shown). Similarly, no staining was observed in CTLs 
Fig. 1. SGLT1 expression and phloridzin-sensitive glucose uptake in activated murine cytotoxic T lympho-
cytes. A: Confocal microscopy of SGLT1 protein expression in cytotoxic mature T cell blasts (CTL) isolated from wild type (upper panels) and SGLT1 knockout (lower panels) mice. The CTLs were subjected to im-
munofluorescent staining using rabbit anti-murine SGLT1 antibody visualized by staining with anti-rabbit 
FITC-conjugated secondary antibody (green). DRAQ-5 dye (blue) was used for nuclear staining. B: Original histograms of the SGLT1 staining in murine cytotoxic T cells (CTL). Histograms represent unstained wild 
type cells (grey filled), wild type cells stained with secondary FITC antibody alone (black line), as well as wild type cells (red line) and SGLT1 knockout cells (blue line) stained with SGLT1 antibody followed by sec-ondary FITC antibody. C: Original Western blots showing expression of SGLT1 in murine CTLs. D: Original histograms of 2-NBD-glucose uptake in CTLs without (black line) or with 1 hour incubation with phloridzin 
(red line). Grey filled histogram shows unstained cells. E: Arithmetic means ± SEM (n = 4) of geometric means for the 2-NBD- glucose uptake into CTL in the absence (black bar) and presence (grey bars) of phlo-
ridzin (0.2 mM) added for the indicated time periods. *** (p<0.001) indicates statistically significant differ-ence from the absence of phloridzin in 2-NBD-glucose uptake.
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isolated from SGLT1 knockout mice (Fig.1A). In a second series of experiments, SGLT1 protein abundance at the surface of CTL was measured by FACS analysis. As illustrated in 
Fig. 1B, SGLT1 is observed in CTL from wild type mice. The fluorescence was approximately one order of magnitude lower in CTL from SGLT1 knockout mice. Staining with secondary antibody resulted in a similarly faint staining. Taken together, the experiments demonstrate expression of SGLT1 in murine CTLs. SGLT1 was further detected by Western blotting in wildtype mice. Again, no clear band was seen in CTLs from SGLT1 knockout mice. The loading 
control α/β-Tubulin was similarly expressed in both genotypes (Fig.1C). Hence, SGLT1 is expressed in activated murine CTLs.In order to determine the contribution of SGLT1 to glucose uptake by CTLs, glucose uptake into CTLs was determined in the absence and presence of SGLT1 inhibitor phloridzin. 
As shown in Fig.1D, incubation with phloridzin resulted in a significant reduction of glucose uptake into CTLs. Similar results were obtained in CTL pretreated for 30 min, 1 h or 2 h as in CTLs exposed to phloridzin without preincubation (Fig. 1E). Additional experiments were performed to discriminate between CD4+ and CD8+ T cells. The phenotype of mature CTLs was determined by FACS analysis (Fig. 2). SGLT1 was expressed in both, CD4+ and CD8+ T cells (Fig. 3). Accordingly, in both, CD4+ and CD8+ T cells, 
glucose uptake was significantly inhibited by phloridzin (Fig. 4A,B).  
Effect of JAK3 inhibitors on glucose uptake in murine CTLsAdditional experiments explored whether JAK3 regulates glucose uptake in CTLs. To this end, CTLs were treated with different JAK3 inhibitors and 2-NBD-glucose uptake determined (Fig. 4C,D). A 12 h incubation with the JAK3 inhibitors WHI-P131/JANEX-1 
(4-(4′-Hydroxyphenyl)amino-6,7-dimethoxyquinazoline, 156 µM), JAK3 Inhibitor VI (0.5 
µM) or WHI-P154 (4-[(3′-Bromo-4′-hydroxyphenyl)amino]-6,7-dimethoxyquinazoline, 
11.2 µM) each resulted in significant reduction in 2-NBD-glucose uptake in CTLs (Fig. 4C,D), pointing to JAK3 sensitive regulation of SGLT1 activity. 
Fig. 2. Phenotype of mature CTL blasts. Mature cytotoxic T cell blasts were analysed with the standard 
multicolor flow cytometry settings and commercially available (BD Biosciences) specific fluorescence con-jugated antibodies - Fluorescein isothiocyanate (FITC) or Phycoerythrin (PE) conjugated anti-CD4, Allo-phycocyanin (APC) or Cyanine 5.5 (Cy5.5) conjugated anti-CD8, PE conjugated anti-CD25, PE conjugated anti-CD62L, APC conjugated anti-CD25, PE conjugated anti-CD98, PE-anti-CD71 and APC anti-TCRbeta. Live cells (>90% of total acquired events) were gated according to their forward scatter and side scatter. The 
cells were again gated for CD8 and CD4 positive cells and respective fluorescence calculated for cells in CD8 
and CD4 gate. Data was analyzed using Cell Quest Pro software (BD Biosciences, Heidelberg, Germany). A: Phenotype of CD8+ T cells B: Phenotype of CD4+ T cells C: Percent CD4+ and CD8+ T cells in the CTL cultures used for experiments.
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JAK3 inhibitors are known to inhibit proliferation of CTLs and induce apoptosis in CTLs and tumors over-expressing JAK3 [9, 72]. Forward scatter was thus determined in parallel to possibly detect induction of apoptosis. In preliminary experiments CTLs were thus incubated 
for several time points with Jak3 inhibitors. As a result, significant reduction in cell size was 
observed at exposure periods ≥16 hour (data not shown). Thus, a 12 hour incubation was chosen and up to this time point forward scatter remained constant (data not shown).Similar to what has been observed for the total CTL population, the JAK3 inhibitors 
significantly reduced glucose uptake in both, CD4+ and CD8+ subtypes of CTLs (Fig. 5).
Expression of SGLT1 in Jurkat T cells and regulation of glucose uptake by SGLT1 inhibitor 
phloridzinFurther studies tested, whether SGLT1 is similarly expressed in the human T cell leukemia Jurkat T cell line [73]. SGLT1 expression in Jurkat T cells was detected with 
immunofluorescence and confocal microscopy. As shown in Fig.6A Jurkat T cells express SGLT1 protein, which is mainly localized in the cell membrane. Caco2 cells, used as positive control, similarly expressed SGLT1 in the cell membrane (Fig. 6A lower lane). The control 
staining with secondary antibody alone did not result in any significant fluorescence signal (Fig. 6A lower lane). 
Fig. 3. Expression of SGLT1 in CD8+ and CD4+ subtype of activated murine cytotoxic T lymphocytes. CTLs were stained with primary murine anti-SGLT1 antibody followed by staining with secondary anti-rabbit FITC conjugated antibody. In addition cells were stained with PE-conjugated anti-CD4 antibody and APC-con-
jugated anti-CD8 antibody. The fluorescence was measured by standard multicolor flow cytometry settings.  PE 
fluorescence measured in FL-2 and APC fluorescence measured in FL-4 channel together with FITC fluorescence measured in channel FL-1 on a FACS calibur (BD, Heidelberg, Germany). A: Gating of total CTL culture for CD8+ and CD4+ subtype of cells and original histograms for SGLT1 stain in CD8+ and CD4+ subtype of cells. Please do note the different scales in the histograms, as the number of CD8+ cells was higher than the number of CD4+ cells. B: Arithmetic means ± SEM (n = 4) of geometric mean for SGLT1 staining in CD8+ (black bar) and CD4+ (white bar) subtype of cells together with total CTL cells (grey bar) . ### (p<0.001) indicates statistically 
significant difference from the CD4+ subtype of cells as well as from total CTLs. C: Arithmetic means ± SEM (n = 4) of geometric mean for SGLT1 mRNA expression in CD8+ (black bar) and CD4+ (white bar) subtype of cells together with total CTL cells (grey bar) . * (p<0.05) indicates statistically significant difference from the CD8+ cells from total CTLs. 
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SGLT1 expression was also analysed by FACS analysis. FACS histograms of Jurkat T cells stained with primary and secondary antibody revealed a staining, which was one order of magnitude larger than the staining obtained with secondary antibody alone (Fig. 6B). SGLT1 was also detected by Western blotting in Jurkat T cells (Fig. 6C). A band of similar size and density was obtained in Caco2 cells as positive control. Hence, SGLT1 is expressed in Jurkat T cells.Again, 2-NBD-glucose uptake was determined to estimate phloridzin sensitive glucose 
uptake into Jurkat T cells. As shown in Fig. 6D, incubation with phloridzin for 1h significantly decreased 2-NBD-glucose uptake into Jurkat T cells (Fig. 6E). Thus, similar to murine CTLs human Jurkat T cells express functional, phoridzin sensitive SGLT1 which marks its functional relevance in human T-cell leukemia.
Effect of JAK3 inhibitors on glucose uptake in Jurkat T cellsSimilar to what has been shown in CTLs, glucose uptake by Jurkat T cells was 
influenced by JAK3 inhibitors. A 12 hours incubation with JAK3 inhibitor I WHI-P131/
Fig. 4. Phloridzin  and JAK3 inhibitor sensitive glucose uptake in CD8+ and CD4+ subtypes of activated mu-
rine cytotoxic T lymphocytes. A: Arithmetic means ± SEM (n = 4) of geometric means for the 2-NBD- glucose uptake into CD8+ cells in the absence (black bar) and presence (grey bars) of phloridzin (0.2 mM) added for 
1 hour. *** (p<0.001) indicates statistically significant difference from the absence of phloridzin in 2-NBD-glucose uptake. B: Arithmetic means ± SEM (n = 4) of geometric means for the 2-NBD- glucose uptake into CD4+ cells in the absence (black bar) and presence (grey bars) of phloridzin (0.2 mM) added for 1 hour. *** 
(p<0.001) indicates statistically significant difference from the absence of phloridzin in 2-NBD-glucose up-take. C: Arithmetic means ± SEM (n = 4) of geometric means for the 2-NBD-glucose uptake into murine CTLs 
without (black bar) or with 12 hours incubation with JAK3 inhibitor 1 WHI-P131/JANEX-1 (4-(4′-Hydroxy-phenyl)amino-6,7-dimethoxyquinazoline, 156 µM) or with JAK3 Inhibitor VI (0.5 µM) (grey bars) added 12 
h prior to the experiment. **(p<0.01), ***(p<0.001) indicates statistically significant difference from the absence of JAK3 inhibitors. D: Arithmetic means ± SEM (n = 4) of geometric means for the 2-NBD-glucose 
uptake into murine CTLs in the absence (black bar) or presence of JAK3 inhibitor WHI-P154 (4-[(3′-Bromo-
4′-hydroxyphenyl)amino]-6,7-dimethoxyquinazoline, 11.2 µM) (grey bar) added 12 h prior to the experi-
ment. ** (p<0.01) indicates statistically significant difference from the absence of JAK3 inhibitors.
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JANEX-1 (4-(4′-Hydroxyphenyl)amino-6,7-dimethoxyquinazoline, 156 µM), JAK3 Inhibitor 
VI (0.5 µM) or JAK3 inhibitor II WHI-P154 (4-[(3′-Bromo-4′-hydroxyphenyl)amino]-6,7-
dimethoxyquinazoline, 11.2 µM) each resulted in a significant reduction in 2-NBD-glucose uptake into Jurkat T cells (Fig. 7A,B). Again, within the exposure time, forward scatter 
remained virtually constant and thus, there was no significant effect of the inhibitors on cell size (Fig. 7C). 
JAK3 expression stimulated SGLT1 activity in Xenopus oocytes, an effect mimicked by 
active mutant A568VJAK3 but not by inactive K851AJAK3
In order to explore more directly whether JAK3 influences the function of SGLT1, the carrier was expressed in Xenopus oocytes with or without JAK3 and glucose induced inward 
Fig. 5. Influence of JAK3 inhibitors on glucose uptake into CD8+ and CD4+ subtypes of  activated murine 
cytotoxic T lymphocytes. A: Original histograms of 2-NBD-glucose uptake in CD8+ cells without (black line) 
or with 12 hours incubation with JAK3 inhibitor 1 WHI-P131/JANEX-1 (4-(4′-Hydroxyphenyl)amino-6,7-
dimethoxyquinazoline, 156 µM) (red line) or with JAK3 Inhibitor VI (0.5 µM) (blue line). Grey filled histogram shows unstained cells. B: Arithmetic means ± SEM (n = 4) of geometric means for the 2-NBD-glucose uptake into murine CD8+ cells in the absence (black bar) or presence of JAK3 inhibitor WHI-P131 or JAK3 inhibitor 
VI (grey bars) added 12 h prior to the experiment. ***(p<0.001) indicates statistically significant difference 
from the absence of JAK3 inhibitors. C: Original histograms of 2-NBD-glucose uptake in CD8+ cells without 
(black line) or with incubation with JAK3 inhibitor WHI-P154 (4-[(3′-Bromo-4′-hydroxyphenyl)amino]-6,7-dimethoxyquinazoline, 11.2 µM) added 12 hours prior to the experiment (blue line). D: Arithmetic means ± SEM (n = 4) of geometric means for the 2-NBD-glucose uptake into murine CD8+ cells in the absence (black bar) or presence of JAK3 inhibitor WHI-P154 (grey bar) added 12 h prior to the experiment. ** (p<0.01) 
indicates statistically significant difference from the absence of JAK3 inhibitors. E: Original histograms of 2-NBD-glucose uptake in CD4+ cells without (black line) or with 12 hours incubation with JAK3 inhibitor 1 
WHI-P131/JANEX-1 (4-(4′-Hydroxyphenyl)amino-6,7-dimethoxyquinazoline, 156 µM) (Red line) or with 
JAK3 Inhibitor VI (0.5 µM) (blue line). Grey filled histogram shows unstained cells. F: Arithmetic means ± SEM (n = 4) of geometric means for the 2-NBD-glucose uptake into murine CD4+ cells in the absence (black bar) or presence of JAK3 inhibitors WHI-P131 or JAK3 Inhibitor VI (grey bars) added 12 h prior to the 
experiment. ***(p<0.001) indicates statistically significant difference from the absence of JAK3 inhibitors. 
G: Original histograms of 2-NBD-glucose uptake in CD4+ cells without (black line) or with incubation with 
JAK3 inhibitor WHI-P154 (4-[(3′-Bromo-4′-hydroxyphenyl)amino]-6,7-dimethoxyquinazoline, 11.2 µM) added 12 hours prior to the experiment (blue line). H: Arithmetic means ± SEM (n = 4) of geometric means for the 2-NBD-glucose uptake into murine CD4+ cells in the absence (black bar) or presence of JAK3 inhibitor 
WHI-P154 (grey bar) added 12 h prior to the experiment. ** (p<0.01) indicates statistically significant difference from the absence of JAK3 inhibitors. Please do note the different scales in B and D as well as in F and H.
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current was taken as measure of glucose transport. In non-injected or water-injected Xenopus 
oocytes, glucose (10 mM) added to extracellular fluid did not induce an appreciable inward current. Thus, Xenopus oocytes do not express appreciable endogenous electrogenic glucose transport (Fig. 8). Glucose-induced current was similarly low in Xenopus oocytes expressing wild type JAK3 alone (Fig. 8A,B). In contrast, glucose (10 mM) induced a strong inward current (Ig) in Xenopus oocytes expressing SGLT1 (SLC5A1). The current was generated by electrogenic entry of Na+ driving glucose transport. Expression of JAK3 in addition to SGLT1 
significantly enhanced Ig (Fig. 8A,B). According to kinetic analysis of the glucose-induced currents in SGLT1-expressing 
Xenopus oocytes (Fig. 8C) the maximal current was significantly higher (95 ± 6 nA, n = 3) in Xenopus oocytes expressing SGLT1 and JAK3 than in Xenopus oocytes expressing SGLT1 alone (64 ± 5 nA, n = 3). The glucose concentration required for half-maximal current (KM) was similar in Xenopus oocytes expressing SGLT1 and JAK3 (891 ± 210 µM, n = 3) and in 
Xenopus oocytes expressing SGLT1 alone (795 ± 196 µM, n = 3). Thus, coexpression of JAK3 enhanced SGLT1 activity at least in part by increasing the maximal current. 
Fig. 6.  SGLT1 expression and phloridzin sensitive glucose uptake in Jurkat T cells. A: Confocal micros-copy of SGLT1 protein expression in Jurkat T cells (upper panels) and colon carcinoma (Caco2) cells (lower panels). The cells were subjected to immunofluorescent staining using rabbit anti-human SGLT1 antibody visualized by staining with anti-rabbit FITC-conjugated secondary antibody (green). DRAQ-5 dye (blue) was used for nuclear staining. Lower panel right picture shows Caco2 cells stained with only secondary 
antibody and DRAQ-5. B: Original histograms of the SGLT1 staining in Jurkat T cells. Histograms represent 
unstained cells (grey filled), cells stained with secondary FITC antibody only (black line) and cells stained with SGLT1 antibody followed by secondary antibody (blue line). C: Original Western blots showing expres-sion of SGLT1 in Jurkat T cells and Caco2 cells. D: Original histograms of 2-NBD-glucose uptake in Jurkat T cells without (black line) or with 1 hour incubation with phloridzin (red line). Grey filled histogram shows unstained cells. E: Arithmetic means ± SEM (n = 4) of geometric means for the 2-NBD- glucose uptake into Jurkat T cells in the absence (black bar) and presence (grey bars) of phloridzin (0.2 mM) added for the indi-
cated time periods. *** (p<0.001) indicates statistically significant difference from the absence of phloridzin in 2-NBD-glucose uptake.
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The effect of JAK3 coexpression was mimicked by coexpression of the active mutant A568VJAK3 but not by the inactive mutant K851AJAK3 (Fig. 8A,B). The effect of A568VJAK3 tended to be 
higher than the effect of wild type JAK3, an effect, however, not reaching statistical significance. 
Pharmacological JAK3 inhibition reversed the effect of JAK3 expression on SGLT1 activity 
in Xenopus oocytes In Xenopus oocytes expressing SGLT1 and JAK3, preincubation of the oocytes with the JAK3 
inhibitor WHI-P154 (4-[(3′-Bromo-4′-hydroxyphenyl)amino]-6,7-dimethoxyquinazoline, 
11.2 µM) was followed by a significant decrease of Ig (Fig. 9A,B). The effect of the inhibitor was 
slow and was not apparent within 30 minutes. The effect reached statistical significance within 6 hours of preincubation of the inhibitors (Fig. 9B). 
Effect of JAK3 and A568VJAK3 on SGLT1 protein abundance in Xenopus oocytesThe up-regulation of SGLT1 activity following coexpression of JAK3 could have resulted from increased carrier protein abundance in the plasma membrane. To explore that possibility, chemiluminescence was employed. As shown in Fig. 10A, the coexpression of JAK3 and A568VJAK3 was followed by a significant increase of SGLT1 protein abundance within the oocyte cell membrane. 
Fig. 7. Influence of JAK3 inhibitors on glucose uptake into Jurkat T cells. A: Original histograms of 2-NBD-glucose uptake in Jurkat T cells without (black line) or with 12 hours incubation with JAK3 inhibitors 1 
WHI-P131/JANEX-1 (4-(4′-Hydroxyphenyl)amino-6,7-dimethoxyquinazoline, 156 µM) (red line), WHI-
P154 (4-[(3′-Bromo-4′-hydroxyphenyl)amino]-6,7-dimethoxyquinazoline, 11.2 µM) (sky blue line) or JAK3 
Inhibitor VI  (0.5 µM) (dark blue line). Grey filled histogram shows unstained cells. B: Arithmetic means ± SEM (n = 6) of geometric means for the 2-NBD-glucose uptake into Jurkat T cells in the absence (black bar) or presence of JAK3 inhibitors WHI-P131, WHI-P154 or JAK3 Inhibitor VI (grey bars) added 12 h prior to 
the experiment. *(p<0.05), ***(p<0.001) indicates statistically significant difference from the absence of 
JAK3 inhibitors. C: Arithmetic means ± SEM (n = 6) of geometric means of forward scatter reflecting cell size of Jurkat T cells in the absence (black bar) or presence of JAK3 inhibitors WHI-P131/JANEX-1 or WHI-P154 or JAK3 Inhibitor VI (grey bars) added 12 h prior to the experiment.
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Fig. 8. Upregulation of electrogenic glucose transport in SGLT1-expressing Xenopus oocytes by wild type JAK3, by A568VJAK3 but not by K851AJAK3. A: Representative original tracings showing glucose (10 mM)-in-duced current (Ig) in Xenopus oocytes injected with water (a) and expressing JAK3 alone (b) or SGLT1 with-out (c) or with additional coexpression of wild type JAK3 (d) or A568VJAK3 (e), or  inactive mutant K851AJAK3 (f). B: Arithmetic means ± SEM (n = 10-15) of glucose (10 mM)-induced current (Ig) in Xenopus oocytes injected with water (H2O), expressing JAK3 alone (JAK3), or expressing SGLT1 without (SGLT1) or with ad-ditional coexpression of wild type JAK3 (SGLT1+JAK3) or SGLT1+A568VJAK3 or SGLT1+K851AJAK3. ***(p<0.001) 
indicates statistically significant difference from the absence of SGLT1. #(p<0.05), ### (p<0.001) indicates 
statistically significant difference from SGLT1 injected alone. C: Arithmetic means ± SEM (n = 3) of glucose induced current (Ig) as a function of glucose concentration in Xenopus oocytes expressing SLC5A1 (SGLT1) without and with JAK3. 
Fig. 9. Downregulation of electrogenic glucose transport in SGLT1+JAK3 expressing Xenopus oo-cytes by pharmacologic JAK3 inhibition. A: Rep-resentative original tracings showing glucose (10 mM)-induced current (Ig) in Xenopus oocytes inject-ed with (left panel) SGLT1 alone (a), or coexpressing SGLT1 with JAK3 without (b), or with a 3 hour (c) or 6 hour (d) or 24 hour (e) pretreatment with JAK3 in-hibitor WHI-P154 (4-[(3′-Bromo-4′-hydroxyphenyl)amino]-6,7-dimethoxyquinazoline, 11.2 µM). B: Arithmetic means ± SEM (n = 6-8) of glucose (10 mM)-induced current (Ig) in Xenopus oocytes injected with SGLT1 without (SGLT1) or with (SGLT1+JAK3) additional coexpression of wild type JAK3 in the ab-sence of inhibitor (0 h) or following a 3 h, 6 h, or 24 h pretreatment with WHI-P154 (4-[(3′-Bromo-4′-hydroxyphenyl)amino]-6,7-dimethoxyquinazoline, 11.2 µM), #(p<0.05) indicates statistically signifi-cant difference from SGLT1 injected alone (absence of JAK3). **(p<0.01), ***(p<0.001) indicates statisti-
cally significant difference from the absence of JAK3 inhibitors (SGLT1+JAK3). 
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Fig. 10. Upregulation of surface SGLT1 protein abundance in SGLT1-expressing Xenopus oocytes by co-expression of JAK3 and A568VJAK3 and effects of actinomycin D and brefeldin A on electrogenic glucose transport. A: Arithmetic means ± SEM (n = 24-39) of the normalized chemiluminescence reflecting SGLT1 protein abundance in Xenopus oocytes injected with SGLT1 alone (SGLT1), or expressing SGLT1 with A568V-JAK3 (SGLT1+ A568VJAK3). #(p<0.05), ###(p<0.001) indicates statistically significant difference from SGLT1 
injected alone. B: Arithmetic means ± SEM (n = 4-7) of glucose (10 mM)-induced current (Ig) in Xenopus oocytes injected with SGLT1 without (white bars) and with JAK3 (black bars) in the presence and absence 
of 10 µM actinomycin D 2-3 days prior to the measurement. ###(p<0.001) indicates statistically significant 
difference from SGLT1 injected alone. C: Arithmetic means ± SEM (n = 12-16) of glucose (10 mM)-induced current (Ig) in Xenopus oocytes injected with SGLT1 without (white bars) and with (black bars) JAK3 in the presence and absence of 5 µM brefeldin A for 0-24 hours prior to the measurement. ###(p<0.001) indicates 
statistically significant difference from SGLT1 injected alone, ***(p<0.001) indicates significant difference from the absence of brefeldin A.
Effect of brefeldin A and actinomycin D on glucose transport in SGLT1+JAK3 expressing 
Xenopus oocytes
JAK3 could have enhanced SGLT1 by influencing transcription of  a posttranscriptional regulator of SGLT1. Thus, in additional experiments SGLT1+JAK3 expressing oocytes were incubated 2-3 days with and without actinomycin D (10 µM), an inhibitor of transcription. As 
a result, actinomycin D did not significantly modify Ig in Xenopus oocytes coexpressing JAK3 and SGLT1 (Fig. 10B). The increased SGLT1 protein abundance in the cell membrane of SGLT1 expressing oocytes following coexpression of JAK3 could have resulted from either accelerated insertion of new carriers into or slowed clearance of carriers from the cell membrane. For discrimination between those two possibilities SGLT1-expressing Xenopus oocytes were treated with 5 µM brefeldin A, which blocks the insertion of new carrier protein into the cell membrane [74].As shown in Fig. 10C, the glucose induced current declined in the presence of brefeldin A at a similar rate in SGLT1 and JAK3 expressing Xenopus oocytes and in oocytes expressing SGLT1 alone, an observation suggesting that JAK3 increases SGLT1 activity by stimulating carrier insertion into rather than by delaying the retrieval of carrier protein from the cell membrane. 
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Discussion
The present study shows for the first time expression of the high affinity Na+ coupled glucose transporter SGLT1 in activated murine cytotoxic T cells and in human Jurkat T cells. The carrier accomplishes uphill transport of glucose driven by Na+ entry down its electrochemical 
gradient. SGLT1 dependent cellular glucose uptake may be of prime significance for glucose uptake and function of CTL under glucose deprived conditions. At ample extracellular glucose concentration some 50% of glucose uptake is phloridzin sensitive and thus mediated by SGLT1. The residual uptake is presumably accomplished by GLUT1 [75], which mediates passive transport and is unable to operate against a chemical glucose gradient [76, 77]. At decreased extracellular glucose the contribution of SGLT1 to cellular glucose uptake is thus expectedly much higher. As soon as extracellular glucose concentration decreases to values lower than intracellular glucose concentration, cellular net glucose uptake fully depends on SGLT1, which, in contrast to glucose carriers of the GLUT family, is able to transport glucose against a glucose gradient [19]. Quiescent naive and memory CD8+ T cells do require energy for survival and migration. Effector CTLs have a substantially higher energy demand because they need to proliferate rapidly and produce effector cytokines [36]. It is thus essential that upon activation, CD8+ T cells increase cellular energy production and nutrient uptake to satisfy increased biosynthetic demands [42]. Following activation, CTLs upregulate amino acid transporters, the transferrin receptor and glucose transporters at the cell surface in response to extrinsic signals from antigens and cytokines [38, 75]. Inhibition of aerobic and anaerobic energy production in effector cells completely abolished cytotoxicity [78], an observation illustrating 
energy requirements for efficient cell-mediated cytotoxicity. In resting T-cells, ATP is largely generated by breakdown of glucose, lipids and amino acids through oxidative phosphorylation, which yields large amounts of ATP [38]. In proliferating lymphocytes, lipid precursors and amino acids are, instead, shunted into the production of macromolecules that are required for anabolic cell growth. As a result, continued ATP production becomes progressively more dependent on the degradation of glucose by glycolysis [79]. Preferential ATP generation from glycolysis is maintained under both aerobic and anaerobic conditions [80, 81]. Thus, even in the presence of oxygen, proliferating lymphocytes generate ATP mainly by glycolysis [38, 82]. If glucose delivery and 
thus glycolytic flux are not sufficient, function and survival of lymphocytes is compromised and proapoptotic Bcl-2 family members become activated thus inducing cell death [42, 79]. Failure to up-regulate the metabolic machinery thus leads to anergic T cells [83]. As compared to oxidative phosphorylation glycolysis yields only a small fraction of 
ATP and sufficient ATP generation from glycolysis requires excessive glucose uptake and consumption [41]. In activated T cells, the switch from oxidative phosphorylation to aerobic glycolysis, i.e. oxygen-independent production of ATP from glucose, is thus paralleled by high-level glucose uptake, which has hitherto been considered to be accomplished by upregulation of expression and function of the glucose carrier GLUT1 (SLC2A1) [75]. The 
present data reveals that SGLT1 also plays a significant role in glucose uptake by CTLs. The function of this carrier may be particularly important for lymphocytes invading in tissues with low extracellular glucose concentrations due an imbalance of glucose delivery from blood and excessive cellular glucose utilization. SGLT1 is mainly expressed in intestinal and renal tubular epithelia [19, 84]. SGLT1 is, however, in addition expressed in a variety of tumor cells [20-27]. Similar to activated lymphocytes [75, 85-87], tumor cells further express the facilitative glucose transporter GLUT1 [76, 77]. It is hypothesized that the facilitative glucose carrier cannot cover the excessive glucose demand of tumor cells under conditions of low extracellular glucose concentrations [22]. The employment of SGLT1 for cellular glucose uptake is a double edged sword, as unlike the passive GLUT carriers, Na+-coupled glucose uptake requires ATP-consuming extrusion of the cotransported Na+ by the Na+/K+ ATPase. Inability to extrude the cotransported Na+ is expected 
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to result in cellular K+ loss, followed by depolarization, Cl- entry, cellular accumulation of NaCl with osmotically obliged water and thus cell swelling [88]. Since Na+/K+ ATPase extrudes 3 Na+ ions for one ATP, the energy required for subsequent extrusion of cotransported Na+ is, however, only a fraction of the energy gained by the degradation of glucose, even if glucose is utilized for ATP generation by glycolysis without oxidative metabolism. 
The present observations also disclose JAK3 as a novel regulator of the high affinity Na+ coupled glucose transporter SGLT1. The pharmacological evidence in CTLs and Jurkat T cells 
has been confirmed by results utilizing the Xenopus oocytes expression system. In Xenopus 
laevis oocytes, JAK3 up-regulates SGLT1 protein abundance in the cell membrane and thus increases the electrogenic cellular glucose uptake. Accordingly, co-expression of JAK3 increased 
the maximal current reflecting maximal glucose transport rate. The experiments with brefeldin 
A suggest that JAK3 influences the insertion of carrier protein into rather than delaying carrier retrieval from the cell membrane.
JAK3 could influence SGLT1 protein abundance in the cell membrane by direct phosphorylation of the carrier protein or by phosphorylation of other signaling molecules, which in turn up-regulate SGLT1. SGLT1 is regulated by JAK2 [18], protein kinase A (PKA) [89, 90], protein kinase C (PKC) [89, 90], serum- and glucocorticoid-inducible kinase [91] and AMP-activated kinase [92]. Similar to JAK3, those kinases modify SGLT1 activity by influencing the carrier protein abundance within the plasma membrane.
Genetic deficiency of JAK3 leads to abrogation of signal transduction through the common 
gamma chain (γc) and thus to immunodeficiency suggesting that specific inhibition of JAK3 may 
result in immunosuppression [93]. Unexpectedly, a JAK3-selective inhibitor was less efficient in abolishing STAT5 phosphorylation than pan-JAK inhibitors [15]. It has been shown that the 
two JAK isoforms involved in signaling through γc utilizing cytokine receptors are not equally important and that JAK1 plays a dominant role over JAK3 [15]. Hence, additional mechanisms 
and regulation by JAK3 in T cells may be responsible for immunodeficiency associated with 
Jak3 deficiency. Inhibition of glucose uptake in CTLs by JAK3 inhibitors may provide a further 
explanation for the immunosuppressive effect of JAK3 deficiency and apoptosis inducing effect of JAK3 inhibitors in T cells. Along those lines downregulation of glucose transport has previously been shown to be an early effector mechanism in CD95-induced apoptosis of activated human T cells [94]. In conclusion, SGLT1 is expressed in murine CTLs and human Jurkat T cells and 
contributes significantly to glucose uptake in those cells. JAK3 up-regulates the Na+-coupled glucose transporter SGLT1 by increasing the carrier protein abundance in the cell membrane. This effect of JAK3 could contribute to cellular glucose delivery in CTLs. 
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